• 1
    Lee WM. Hepatitis B infection. N Engl J Med 1997; 337: 17331745.
  • 2
    Lok A, McMahon BJ. AASLD chronic hepatitis B: update of recommendations. HEPATOLOGY 2004; 39: 857861.
  • 3
    Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, et al. Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 979981.
  • 4
    Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, Cheng YC. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosylurail. Biochem Pharmacol 1996; 51: 941947.
  • 5
    Chin R, Shaw T, Torresi J, Earnest-Silveira L, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type and drug-resistant hepatitis B virus to (-)-β–D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45: 24952501.
  • 6
    Pai SB, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob Agents Chemother 1996; 40: 380386.
  • 7
    Ma T, Pai SB, Zhu YL, Lin JS, Shanmuganathan K, Du J, et al. Structure-activity relationships of 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyluracil) pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996; 39: 28352843.
  • 8
    Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998; 42: 833839.
  • 9
    Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5–methyl β-L-arabinofuranosyl)uracil)] against woodchuck hepatitis virus and gene expression in chronically infected woodchucks (Marmota monax). HEPATOLOGY 2001; 33: 254266.
  • 10
    Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998; 3(Suppl 3): 113121.
  • 11
    Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311322.
  • 12
    Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci U S A 2004; 101: 638640.
  • 13
    Marcellin P, Mommeja-Marin H, Sacks SL, Lau GKK, Sereni D, Bronowicki JP, et al. A phase II dose escalating trial of clevudine in patients with chronic hepatitis B. HEPATOLOGY 2004; 40: 140148.
  • 14
    Lee HS, Chung YH, Lee KS, Byun KS, Paik SW, Han JY, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. HEPATOLOGY 2006; 43: 982988.
  • 15
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. HEPATOLOGY 1998; 27: 17111716.
  • 16
    Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 18311838.
  • 17
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 18
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 26822695.
  • 19
    Perrillo RP. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis 2005; 25: S20S28.
  • 20
    Sum SS, Wong DK, Yuen MF, Yuan HJ, Yu J, Lai CL, et al. Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA. J Clin Microbiol 2004; 42: 34383440.
  • 21
    Lindh M, Hannoun C. Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real-time semiautomated assay. J Clin Microbiol 2005; 43: 42514254.
  • 22
    Menne S, Ronecker CA, Korba BE, Gerin JL, Tennant BC, Cote PJ. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 2002; 76: 53055314.
  • 23
    Yeh C-T, Chien R-N, Chu C-M, Liaw Y-F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. HEPATOLOGY 2000; 31: 13181326.
  • 24
    Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B [Abstract]. J Hepatol 2005; 42: 36A.